You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Utilization of cord blood-expanded stem cells for megakaryocyte and platelet production

    SBC: AllCells, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Platelet transfusions are the most effective treatments for patients with thrombocytopenia The growing demand for platelet transfusions is often limited by shortage in the platelets PTL supply due to dependency on volunteer donors short shelf life risk of infections and alloimmunization It is therefore critical to create an efficient donor independent ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. A Tool for Research on Emotion in Naturally Occurring Speech

    SBC: Converspeech LLC            Topic: NLM

    DESCRIPTION provided by applicant A Tool for Research on Emotion in Naturally Occurring Speech It is now widely accepted that defects or limitations in emotion processing underlie many disorders such as anxiety depression bipolar and eating disorders If bio behavioral markers of emotions could be found researchers would have the basis for investigating emotions in both normal mental functi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. An Agent-Based Modeling Platform for Environmental Biotechnology

    SBC: MICROVI BIOTECH, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant Hazardous compounds in waters and soils are subject to a complex dynamic web of interactions among physical chemical and biological constituents in the natural environment Computational modeling has been proven indispensable to hazardous substances remediation particularly integrated modeling of pollutant hydrogeological fate and transport For the first t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a kit for characterization of cellular energetics in single cells in cell and tissue cultures based on the measurement of the absolute magnitude of the mitochondrial membrane potential

    SBC: Gerencser, Akos            Topic: R41

    DESCRIPTION provided by applicant Altered cellular energetics contributes to human disease in general physiological aging and chronic diseases in particular including cancer neurodegeneration ischemic heart disease and type diabetes Pathological changes affecting the individual may arise only in specific cells of a tissue and potentially in a heterogeneous manner To advance basic resea ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Small, high-affinity ligands for array tomography

    SBC: ARATOME, LLC            Topic: 101

    DESCRIPTION provided by applicant Neurodegenerative diseases are among the most expensive disruptive and least well treated of human maladies arguably because they are not well understood Array tomography AT is a method for tissue imaging with resolution in all three dimensions sufficient to resolve individual synapses and provide quantitative characterization ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Pharmacological chaperones for the treatment of Open-Angle Glaucoma

    SBC: Viewpoint Therapeutics, Inc.            Topic: NEI

    Open-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. A platform for engineering peptide ligase for building next generation peptide therapeutics.

    SBC: SCRIBE BIOSCIENCES, INC.            Topic: 400

    PROJECT SUMMARY There is an increased interest in peptide medicines in pharmaceutical research and development (Randamp;D) because peptides are recognized as highly selective and efficacious, and at the same time relatively safe and well tolerated. Chemo-enzymatic peptide synthesis (CEPS) using peptide ligases features excellent purity and yield, thus becoming an attractive method to replace tradi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system

    SBC: FasCure Therapeutics LLC            Topic: NIAID

    DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government